Amyloid targeting agents

A compound of formula:

• or a pharmaceutically acceptable salt, tautomer or a prodrug thereof wherein:
• W1 is O, N(R14), or C(R4)2;
• R14 is hydrogen, alkyl, halomethyl having 1 to 3 halo groups, —COOH, —CONH2, substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• R1 is selected from hydrogen, halo, haloalkyl having 1 to 3 halo groups, or cyano;
• R2, R3, R4, R5, and R6 are each independently hydrogen, halo, haloalkyl having 1 to 3 halo groups, —CN, —C(O)R1A, —C(O)OR1A, —C(O)NR1AR1B, —OR1A, —NHC(O)NR1AR1B, —NR1AR1B, —NHNR1AR1B, —NR1AC(O)R1B, —NR1AC(O)OR1B, —NR1AOR1B, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• R1A and R1B are each independently hydrogen, halo, haloalkyl having 1 to 3 halo groups, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• Z is —C(O)— or —SO2—;
• and
• Y is CH2, NH, or S;
• and
• WSG is a water soluble group;
• with the proviso that:
• when Z is —C(O)—, then Y is not NH,
• when Y is CH2, W1 is O, N(CH3), or CH2 for formula I, then R2 is not hydrogen or C1-10 alkyl, and
• when Y is CH2, W1 is O, N(CH3), or CH2, and R3, R5, R6 are hydrogen for formula II, then R2 is not hydrogen or C1-10 alkyl.